Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TripSitter ClinicTSTTF -78.27%20 EV-to-EBITDA is -27.80 as of Aug. 27, 2026. GuruFocus rates TSTTF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 518 Healthcare Providers & Services companies, TripSitter Clinic ranks worse than 193050% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TripSitter Clinic's enterprise value is $2.67 Mil.
TripSitter Clinic's EBITDA for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.10 Mil. Therefore, TripSitter Clinic's EV-to-EBITDA for today is -27.80.
The historical rank and industry rank for TripSitter Clinic's EV-to-EBITDA or its related term are showing as below:
TSTTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.96 Med: -1.89 Max: -0.25
Current: -26.96
During the past 5 years, the highest EV-to-EBITDA of TripSitter Clinic was -0.25. The lowest was -26.96. And the median was -1.89.
TSTTF's EV-to-EBITDA is ranked worse than 100% of 518
companies
in the Healthcare Providers & Services industry
Industry Median: 10.545
vs TSTTF: -26.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TripSitter Clinic's PE Ratio (TTM) for today is calculated as:
TripSitter Clinic's share price for today is $0.0219.
TripSitter Clinic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for TripSitter Clinic's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, TripSitter Clinic's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TripSitter Clinic EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TripSitter Clinic's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TripSitter Clinic's EV-to-EBITDA falls into.
TripSitter Clinic's current Enterprise Value is $2.67 Mil.
TripSitter Clinic's EBITDA for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TripSitter Clinic (TSTTF) has a EV-to-EBITDA of -27.80 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TripSitter Clinic. According to the industry distribution chart, TripSitter Clinic ranks #999999 out of 518 companies in the Healthcare Providers & Services industry.
Is TripSitter Clinic's EV-to-EBITDA too high?
TripSitter Clinic's current EV-to-EBITDA is -27.80. Based on the distribution chart, TripSitter Clinic ranks #999999 out of 518 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TripSitter Clinic has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TripSitter Clinic's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, TripSitter Clinic ranks #999999 out of 518 companies for EV-to-EBITDA. This places TripSitter Clinic in the lower half of its industry. The industry median EV-to-EBITDA is 10.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.55, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TripSitter Clinic. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TripSitter Clinic's current EV-to-EBITDA is -27.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TripSitter Clinic stock overvalued right now?
TripSitter Clinic (TSTTF) has a current EV-to-EBITDA of -27.80. The current EV-to-EBITDA is -27.80. TripSitter Clinic's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For TripSitter Clinic (TSTTF), the current EV-to-EBITDA is -27.80 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TripSitter Clinic Ltd is a consultative virtual clinic and telehealth platform that connects prospective patients to a licensed physician in the United States who can evaluate for a prescribed treatment program of low-dose, oral ketamine medication. Its revenues are generated from the provision of initial consultations and monthly subscriptions to patients seeking mental health treatment that includes legal psychedelic medicine connected with licensed medical practitioners, and also it earns revenue from the sale of monthly subscription plans in the United States.
20GF Score
Get the complete analysis for TSTTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSTTF has been successfully added to your 
